% Held by Insiders1: 68.79%
% Held by Institutions1: 26.20%
This sets up for much bigger price swings short term
Next quarter's average estimate for revenue is $28.3 million. On the bottom line, the average EPS estimate is -$0.05.
Next year's average estimate for revenue is $119.7 million. The average EPS estimate is -$0.11.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pernix Therapeutics Holdings is outperform, with an average price target of $12.40.
Bigger upswings to where and when. Somaxon shareholders got defrauded on this deal.